What factors would you consider when deciding between tamoxifen vs OFS/AI in premenopausal women with early stage HR+ breast cancer?

I think the question is asking when would I recommend tamoxifen alone versus aromatase inhibitor plus medical ovarian suppression with agents like goserelin or leuprolide in a premenopausal breast cancer patient. There are multiple factors to consider. If she has a history of active endometriosis or hypercoagulable state, I try to avoid tamoxifen. Also based on the data from BIG 1-98, if the patient has a T1c or higher N0 or N+ lobular breast cancer, I prioritize the use of an aromatase inhibito...